Hyperhidrosis Clinical Trial
Official title:
Antiperspirant in the Treatment of Residual Limp Hyperhidrosis for Prosthetic Users: a Pilot Study
Verified date | April 2023 |
Source | Sophies Minde Ortopedi |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The aim of the present pilot study is to evaluate the effect of antiperspirant to treat residual limb hyperhidrosis with the emphasis on the utility of the iodine-starch test to identify the location of the sweating.
Status | Completed |
Enrollment | 7 |
Est. completion date | March 30, 2023 |
Est. primary completion date | December 31, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Over 18 years, 2. used a prosthetic for at least 1 year, 3. HDSS score of = 2, 4. use the prosthetic daily and be able to walk for a minimum of 10 minutes. Exclusion Criteria: 1. Open wounds on the stump, 2. Known sensitivity or allergy to iodine and/or starch, 3. Known sensitivity to antiperspirant. |
Country | Name | City | State |
---|---|---|---|
Norway | Sophies Minde Ortopdi AS | Oslo |
Lead Sponsor | Collaborator |
---|---|
Sophies Minde Ortopedi |
Norway,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Hyperhidrosis Disease Severity Scale (HDSS) | The HDSS is a short single-item scale that is scored from 1-4 and provides a qualitative measure of the severity of sweating based on the extent to which sweating affects daily activities. | Four weeks | |
Primary | Sweating Intensity Visual Scale (SIVS) | In connection with the Minor test, it is also recommended to use the Sweating Intensity Visual Scale (SIVS) in order to provide a more objective and standardized interpretation of the results of the Minor test. SIVS is graded on a scale from 0-V (Grade 0= minimal or no sweating, Grade I = initial, discrete sweating, Grade II = mild sweating, Grade III = moderate sweating, Grade IV = intense sweating, and Grade V= oversweating) | Four weeks | |
Secondary | Numerical Ranking Scale (NRS 100) | Numerical Ranking Scale (NRS 100) (with 0 as low and 100 as high) is used to investigate the following question:
How much sweating do you experience on the stump? How much does sweating affect your function? How much does sweating reduce your quality of life? How much does sweating affect walking related to instability? How much does sweating affect your activity level? How much does sweating affect your skin quality on the stump |
Four weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04924036 -
Qbrexza Cloths for Hyperhidrosis of Amputation Sites
|
Phase 2 | |
Recruiting |
NCT05102396 -
Topical Oxybutynin for Treatment of Hyperidrosis: Local or Systemic Effect?
|
Phase 2 | |
Recruiting |
NCT04178161 -
Image Guided Targeted Photoablation for the Treatment of Localized Hyperhidrosis
|
N/A | |
Completed |
NCT02565732 -
Safety and Efficacy of Botulinum Toxin Type A Topical Gel for Primary Axillary Hyperhidrosis
|
Phase 2 | |
Completed |
NCT02552199 -
A Non-Interventional Study To Assess Sweating
|
||
Recruiting |
NCT01930604 -
Botulinum Toxin Treatment in Craniofacial, Inguinal, Palmar, Plantar and Truncal Hyperhidrosis
|
Phase 2 | |
Completed |
NCT01811004 -
Evaluation of 1440nm Laser vs. Botulinum Toxin or miraDry® Microwave For Treatment of Axillary Hyperhidrosis
|
N/A | |
Completed |
NCT01671800 -
Study to Assess the Efficacy of Botulinum Toxin B (Myobloc) for the Treatment of Prosthesis-associated Sweating
|
Phase 1 | |
Completed |
NCT01956591 -
Long Term Results of the Use of Oxybutynin for the Treatment of Hyperhidrosis
|
N/A | |
Completed |
NCT01934153 -
Characterization of Exposure From Topical Administration of [14C] Umeclidinium to Axilla or Palm of Healthy Male Subjects
|
Phase 1 | |
Completed |
NCT06113978 -
Thoracoscopic Sympathetic Chain Interruption for Palmar Hyperhidrosis in Patients Below 18
|
N/A | |
Completed |
NCT04906655 -
An Open Label Study for Palmar Hyperhydrosis
|
Phase 2 | |
Completed |
NCT05247333 -
Implementation of a Minor Ailment Service in Community Pharmacy Practice
|
N/A | |
Completed |
NCT02563899 -
Pharmacokinetic, Safety, Tolerability, and Clinical Effect of Topical Umeclidinium in Primary Axillary Hyperhidrosis
|
Phase 2 | |
Withdrawn |
NCT05546710 -
miraDry Post Market Tumescent Anesthesia Study
|
N/A | |
Completed |
NCT02016885 -
A Dose-Ranging Study of the Effect of Glycopyrrolate in Subjects With Axillary Hyperhidrosis
|
Phase 2 | |
Completed |
NCT00168480 -
A Study Using Botulinum Toxin Type A in Patients With Axillary Hyperhidrosis
|
Phase 4 | |
Completed |
NCT03416348 -
Hyperhidrosis, Developing a Treatment Approach Aims 1 & 2
|
Phase 1 | |
Completed |
NCT02973659 -
The Use of Topical Oxybutynin 10% for Treating Primary Focal Hyperhidrosis-axillary, Palmar and Plantar.
|
N/A | |
Recruiting |
NCT05805696 -
Treatment and Mapping of Impostor Phenomenon
|
N/A |